Cutler Group’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-400
Closed -$19K 5033
2022
Q2
$19K Sell
400
-1,000
-71% -$13.4K ﹤0.01% 2702
2022
Q1
$16K Sell
1,400
-49,600
-97% -$922K ﹤0.01% 3232
2021
Q4
$124K Buy
51,000
+17,900
+54% +$616K 0.01% 1688
2021
Q3
$96K Buy
33,100
+32,100
+3,210% +$1.76M ﹤0.01% 1950
2021
Q2
$13K Buy
1,000
+600
+150% +$22.2K ﹤0.01% 3670
2021
Q1
$12K Sell
400
-100
-20% -$5.7K ﹤0.01% 3635
2020
Q4
$11K Buy
+500
New +$20.5K ﹤0.01% 3114
2019
Q4
Sell
-4,100
Closed -$38K 4113
2019
Q3
$38K Sell
4,100
-200
-5% -$4.95K ﹤0.01% 1734
2019
Q2
$36K Buy
4,300
+200
+5% +$4.77K ﹤0.01% 1788
2019
Q1
$39K Sell
4,100
-5,600
-58% -$127K ﹤0.01% 1592
2018
Q4
$52K Hold
9,700
﹤0.01% 1446
2018
Q3
$30K Sell
9,700
-5,200
-35% -$168K ﹤0.01% 1962
2018
Q2
$42K Buy
14,900
+1,200
+9% +$42.5K ﹤0.01% 1716
2018
Q1
$59K Sell
13,700
-15,700
-53% -$559K 0.01% 1546
2017
Q4
$84K Buy
29,400
+13,500
+85% +$340K ﹤0.01% 1495
2017
Q3
$26K Sell
15,900
-17,300
-52% -$329K ﹤0.01% 2867
2017
Q2
$91K Buy
33,200
+25,400
+326% +$458K ﹤0.01% 1943
2017
Q1
$11K Buy
+7,800
New +$162K ﹤0.01% 3930
2016
Q4
Sell
-700
Closed -$4K 6676
2016
Q3
$4K Buy
+700
New +$14.3K ﹤0.01% 5120

Other funds holding EDIT

Cutler Group's EDIT Position: Q1 2023 in Review

Cutler Group sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 100 shares.

Cutler Group first reported a position in EDIT in Q1 2017 and held it in 24 quarters. The position peaked at $409K in Q4 2021. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

  • Cutler Group reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 100 Editas Medicine shares in Q1 2023.
  • Cutler Group first reported a position in Editas Medicine in Q1 2017 and held it in 24 quarters.
  • Cutler Group's Editas Medicine position peaked at $409K in Q4 2021.
  • 234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.